These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20162187)

  • 1. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease.
    Perez LR; Franz KJ
    Dalton Trans; 2010 Mar; 39(9):2177-87. PubMed ID: 20162187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reorganizing metals: the use of chelating compounds as potential therapies for metal-related neurodegenerative disease.
    Badrick AC; Jones CE
    Curr Top Med Chem; 2011; 11(5):543-52. PubMed ID: 21189128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelating agents for neurodegenerative diseases.
    Ward RJ; Dexter DT; Crichton RR
    Curr Med Chem; 2012; 19(17):2760-72. PubMed ID: 22489724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal Ions in Alzheimer's Disease: A Key Role or Not?
    Liu Y; Nguyen M; Robert A; Meunier B
    Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of oxidative stress and other pathologies in Alzheimer's disease.
    Simunkova M; Alwasel SH; Alhazza IM; Jomova K; Kollar V; Rusko M; Valko M
    Arch Toxicol; 2019 Sep; 93(9):2491-2513. PubMed ID: 31440798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations.
    Jellinger KA
    Int Rev Neurobiol; 2013; 110():1-47. PubMed ID: 24209432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
    Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
    Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
    [No Abstract]   [Full Text] [Related]  

  • 8. Prochelator strategies for site-selective activation of metal chelators.
    Oliveri V; Vecchio G
    J Inorg Biochem; 2016 Sep; 162():31-43. PubMed ID: 27297691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases.
    Mckenzie-Nickson S; Bush AI; Barnham KJ
    Curr Top Med Chem; 2016; 16(27):3058-3068. PubMed ID: 26881708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases.
    Lanza V; Milardi D; Di Natale G; Pappalardo G
    Curr Med Chem; 2018 Feb; 25(4):525-539. PubMed ID: 28521682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders.
    Giampietro R; Spinelli F; Contino M; Colabufo NA
    Mol Pharm; 2018 Mar; 15(3):808-820. PubMed ID: 29323501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
    Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
    Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelating strategies in systemic metal overload, neurodegeneration and cancer.
    Gumienna-Kontecka E; Pyrkosz-Bulska M; Szebesczyk A; Ostrowska M
    Curr Med Chem; 2014; 21(33):3741-67. PubMed ID: 25005181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword.
    Hegde ML; Hegde PM; Rao KS; Mitra S
    J Alzheimers Dis; 2011; 24 Suppl 2(0 2):183-98. PubMed ID: 21441656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional 8-hydroxyquinoline-appended cyclodextrins as new inhibitors of metal-induced protein aggregation.
    Oliveri V; Attanasio F; Puglisi A; Spencer J; Sgarlata C; Vecchio G
    Chemistry; 2014 Jul; 20(29):8954-64. PubMed ID: 24863958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of metals in Alzheimer's disease.
    Das N; Raymick J; Sarkar S
    Metab Brain Dis; 2021 Oct; 36(7):1627-1639. PubMed ID: 34313926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.